Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human HepG2 cells expressing gain-of-function mutant D374Y-PCSK9
We have transfected Hep2G cells with the gain-of-function mutant D374Y-PCSK9.
ORGANISM(S): Homo sapiens 
2008-01-30 | E-MEXP-1235 | biostudies-arrayexpress
ProteomicsA common human PCSK9 germline variant drives breast cancer metastasis via the LRP1 receptor
Identifying patients at risk for metastatic relapse is a critical need in oncology. We identified a common missense germline variant in PCSK9 (rs562556) that associates with reduced breast cancer survival outcomes in multiple cohorts. Genetic modeling of this gain-of-function single nucleotide varia...
ORGANISM(S): Mus musculus (Mouse) 
2024-12-05 | PXD049279 | Pride
Breast cancer  pcsk9 
GenomicsPCSK9 promotes vein graft lesion development
PCSK9 promotes vein graft lesion development
PRJNA862083 | ENA
ProteomicsSECRETOME DATA only from “Selective stalling of human translation through small molecule engagement of the ribosome nascent chain”
Human genetics as well as pharmacological intervention reveal that Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) plays a key role in regulating the levels of plasma low density lipoprotein cholesterol (LDL-C). Here we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by...
ORGANISM(S): Homo sapiens (Human) 
2017-03-27 | PXD005822 | Pride
Translational stalling Cell lysate Silac Pcsk9 Huh7 cells Secretome 
GenomicsTargeting myeloid-PCSK9 enhancing cardio-protection beyond LDL cholesterol-lowering
Targeting myeloid-PCSK9 enhancing cardio-protection beyond LDL cholesterol-lowering
PRJNA1200779 | ENA
GenomicsPCSK9, a promising novel target for age-related cardiovascular dysfunction
PCSK9, a promising novel target for age-related cardiovascular dysfunction
PRJNA937728 | ENA
GenomicsPCSK9 knockdown in EndoC-bH1 cells at 72 hours
PCSK9 knockdown in EndoC-bH1 cells at 72 hours
PRJNA754177 | ENA
GenomicsSmall Molecule PCSK9 Inhibitors: Hit to lead optimization
Small Molecule PCSK9 Inhibitors: Hit to lead optimization
PRJNA433685 | ENA
GenomicsEngineering chimeric PCSK9 for a vaccine against atherosclerosis
Engineering chimeric PCSK9 for a vaccine against atherosclerosis
PRJNA1188181 | ENA
ProteomicsInteractome analysis of Adenylyl cyclase-associated protein 1
The direct inflammatory action of proprotein convertase subtilisin/kexin type 9 (PCSK9) is examined in vitro in monocytes and endothelial cells, as well as via an in vivo atherosclerosis animal model. PCSK9 exacerbates atherosclerosis in low-density lipoprotein receptor (LDLR)-/- mice, indicating an...
ORGANISM(S): Homo sapiens (Human) 
2024-06-16 | PXD047058 | Pride
Cap1 Human Interactome Pcsk9 
Sort   by:  
 Page size